文献速递创伤与烧伤重症综合管理与镇静镇痛

后CRASH-2时代接受氨甲环酸的成人创伤患者死亡率和并发症发生率:单中心经验

Mortality and Complication Rates in Adult Trauma Patients Receiving Tranexamic Acid: A Single-center Experience in the Post-CRASH-2 Era.
PubMed 文献 · Acad Emerg Med · 2020-03-19
一句话结论美国一级创伤中心接受氨甲环酸的成人创伤患者28天死亡率12.8%与CRASH-2试验相似,但急性血栓栓塞事件发生率6.6%高于CRASH-2的2.0%。

该单中心回顾性研究纳入2014年7月至2017年6月接受氨甲环酸(TXA)的273例成人创伤患者,平均年龄43.8岁,平均给药时间距受伤1.55小时,83.9%在3小时内给药。28天死亡率12.8%(95%CI 8.9%-16.7%),与CRASH-2试验的14.5%(95%CI 13.9%-15.2%)相似;急性血栓栓塞事件发生率6.6%(95%CI 3.7%-9.5%),高于CRASH-2的2.0%(95%CI 1.73%-2.27%)。本队列手术率64.8% vs CRASH-2 47.9%,输血率74.0% vs 50.4%。作者认为患者特征、损伤严重度、TXA剂量及手术和输血率差异可能解释上述观察到的差异,需进一步研究TXA使用中血栓栓塞事件的发生率和危险因素。

要点

  • 本单中心回顾性研究纳入273例成人创伤患者,28天死亡率为12.8%(95%CI 8.9%-16.7%)。
  • 急性血栓栓塞事件发生率为6.6%(95%CI 3.7%-9.5%),高于CRASH-2试验的2.0%(95%CI 1.73%-2.27%)。
  • 83.9%的患者在伤后3小时内接受TXA,平均给药时间为伤后1.55小时。
  • 本队列手术率64.8% vs CRASH-2 47.9%,输血率74.0% vs 50.4%。
  • 作者认为患者特征、损伤严重度、TXA剂量及手术和输血率差异可能解释观察到的差异。

适用人群与场景

  • 年龄18岁及以上、急性损伤后接受TXA的成人创伤患者,来自美国一级创伤中心,时间范围为2014年7月至2017年6月。
  • 排除口服TXA、因择期手术或非创伤指征接受TXA、伤后8小时或更晚接受TXA、以及到达急诊科时心脏骤停的患者。

研究设计与关键结果

  • 研究类型为单中心回顾性研究,纳入273例成人创伤患者,平均年龄43.8(±18.7)岁。
  • TXA平均给药时间为伤后1.55(±1.2)小时,229例(83.9%)在3小时内给药。
  • 28天死亡率12.8%(95%CI 8.9%-16.7%),与CRASH-2试验的14.5%(95%CI 13.9%-15.2%)相似。
  • 急性血栓栓塞事件发生率6.6%(95%CI 3.7%-9.5%),高于CRASH-2试验的2.0%(95%CI 1.73%-2.27%)。
  • 本队列手术率64.8% vs CRASH-2 47.9%,输血率74.0% vs 50.4%。

证据类型、等级与局限

  • 证据类型:单中心回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为患者特征、损伤严重度、TXA剂量及手术和输血率差异可能解释本队列与CRASH-2试验观察到的差异。
  • 作者指出需进一步研究以提供TXA使用中血栓栓塞事件发生率和危险因素的额外见解。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: The CRASH-2 trial demonstrated that tranexamic acid (TXA) in adults with significant traumatic hemorrhage safely reduces mortality. Given that the CRASH-2 trial did not include U.S. sites, our objective was to evaluate patient characteristics, TXA dosing strategies, and the incidence of mortality and adverse events in adult trauma patients receiving TXA at a U.S. Level I trauma center in the post-CRASH-2 era.

METHODS: We conducted a retrospective study that included patients aged 18 years or older who received TXA after an acute injury from July 2014 to June 2017. We excluded patients who received TXA orally, patients who received TXA for elective surgical procedures or nontrauma indications, patients who received it 8 hours or longer after the time of injury, and patients with cardiac arrest at time of emergency department arrival. Trained abstractors collected data from the trauma registry and hospital electronic medical records. Our primary outcome measures were in-hospital death and acute thromboembolic events within 28 days from injury.

RESULTS: We included 273 patients with a mean (±SD) age of 43.8 (±18.7) years. The mean (±SD) time of administration of TXA from time of injury was 1.55 (±1.2) hours with 229 patients (83.9%) receiving TXA within 3 hours. The overall mortality within 28 days from injury was 12.8% (95% confidence interval [CI] = 8.9% to 16.7%), which was similar compared to that in the CRASH-2 trial (14.5%, 95% CI = 13.9% to 15.2%). The incidence of acute thromboembolic events was 6.6% (95% CI = 3.7% to 9.5%), which was higher than that in the CRASH-2 trial (2.0%, 95% CI = 1.73% to 2.27%). Patients in our cohort also received surgery (64.8% vs. 47.9%) and blood transfusions (74.0% vs. 50.4%) more frequently than those in the CRASH-2 cohort.

CONCLUSIONS: Adult trauma patients receiving TXA had similar incidences of death but higher incidences of thromboembolic events compared to the CRASH-2 trial. Variation in patient characteristics, injury severity, TXA dosing, and surgery and transfusion rates could explain these observed differences. Further research is necessary to provide additional insight into the incidence and risk factors of thromboembolic events in TXA use.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Erramouspe PJ, García-Pintos MF, Benipal S, et al. Mortality and Complication Rates in Adult Trauma Patients Receiving Tranexamic Acid: A Single-center Experience in the Post-CRASH-2 Era. Acad Emerg Med. 2020. PMID: 32189440. doi:10.1111/acem.13883

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。